Skip to content
DataLookout
Menu

NCT07907991

The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Trial sites expanded: 0 → 26 locations
    • Primary completion moved earlier from Dec 12, 2029 to Nov 12, 2029
    • Study completion moved earlier from Jan 9, 2030 to Dec 10, 2029
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Annualised rate of moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (number of events per person per year)
Timeframe: Up to week 76

Secondary (9)

Time to first moderate or severe AECOPD
Time to first severe AECOPD
Achievement of St George's Respiratory Questionnaire (SGRQ) response (decrease in total score by ≥4 points from baseline) at week 52
Absolute change from baseline in post-Bronchodilator (BD) forced expiratory volume in 1 second (FEV1) (milliliters) at week 52
Annualised rate of severe AECOPD
Show 4 moreShow less
Absolute change from baseline in SGRQ total score at week 52
Achievement of Evaluating Respiratory Symptoms E-RS: COPD response (decrease by ≥2 points from baseline) at week 52
Achievement of Chronic Airways Disease Assessment Test (CAAT) response (decrease by ≥2 points from baseline) at week 52
Absolute change from baseline in post-BD Forced expiratory volume in 1 second percent predicted (FEV1pp) at week 52

Arms and interventions

Verducatib treatment groupExperimental
Placebo groupPlacebo comparator

Drugs: Verducatib, Placebo matching verducatib

Sites

26 sites in 3 countries

United States 18, Italy 4, Malaysia 4